Grand Rapids, MINCT07361562Now EnrollingIRB Ready

Advanced Solid Tumor, Adult Clinical Trial in Grand Rapids, MI

Access cutting-edge advanced solid tumor, adult treatment through this clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.

Sponsored by Cogent Biosciences, Inc.

Quick Self-Assessment

See if you qualify for this Grand Rapids location

Preparing your pre-screening questions…

Expert Care in Grand Rapids

Access advanced solid tumor, adult specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related advanced solid tumor, adult treatment provided free

Apply for This Grand Rapids Location

Check if you qualify for this advanced solid tumor, adult clinical trial in Grand Rapids, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Grand Rapids

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Grand Rapids site if eligible
  4. 4Begin participation

About This Advanced Solid Tumor, Adult Study in Grand Rapids

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.

Sponsor: Cogent Biosciences, Inc.

Who Can Participate

Inclusion Criteria

Have histologically confirmed diagnosis of:
Part A: Locally advanced, metastatic, and/or unresectable solid tumor with documented ERBB2-activating alteration or NRG1 gene fusion in blood and/or tumor or HER2 overexpression in tumor
Part B: Locally advanced, metastatic, and/or unresectable NSCLC with documented ERBB2 mutation in blood and/or tumor
Part C: Locally advanced, metastatic and/or unresectable breast cancer with documented ERBB2 mutation in blood and/or tumor or HER overexpression in tumor
Have measurable disease per RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 for Part A. For Parts B and C, ECOG Performance Status must be 0 to 2.
Have clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits.

Exclusion Criteria

Received small molecule chemotherapy or anticancer therapies or radiotherapy within certain timeframes before first dose of study drug.
Major surgeries (eg, craniotomy and thoracotomy) within 4 weeks of the first dose of study drug.
Treatment with palliative focal radiotherapy (cranial or extracranial) (eg, stereotactic radiosurgery or intensity-modulated radiation therapy) ≤2 weeks before the first dose of study drug; treatment with whole-brain radiotherapy ≤4 weeks before the first dose of study drug.
Clinically significant cardiac disease.
Resolution of toxicities from prior therapy to ≤Grade 1 (or baseline), including resolution of clinically significant laboratory abnormalities, before the first dose of study drug.
Restrictions on use of corticosteroid use to manage neurologic symptoms in different parts of the study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Grand Rapids?

Yes, this clinical trial (NCT07361562) has an active research site in Grand Rapids, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumor, Adult Treatment Options in Grand Rapids, MI

If you're searching for advanced solid tumor, adult treatment options in Grand Rapids, MI, this clinical trial (NCT07361562) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Grand Rapids research site is actively enrolling participants for this clinical trial. You'll receive care from experienced advanced solid tumor, adult specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumor, adult clinical trials near you to find additional studies recruiting in your area.

More Advanced Solid Tumors Trials in Grand Rapids, MI

See all advanced solid tumors clinical trials recruiting in Grand Rapids — not just this study.

Browse Advanced Solid Tumors Trials in Grand Rapids →

Browse More Trials by Condition

Advanced Solid Tumors TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Grand Rapids?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Grand Rapids, MI